Primary source: European Medicines Agency (EMA)
EMA released an update to Appendix 1 of the nitrosamines referral, setting revised acceptable intake limits for nitrosamine impurities in human medicinal products.
Nitrosamine impurities are potential carcinogens; updated limits ensure patient safety and require manufacturers to reassess and control impurity levels in their products.
Manufacturers must verify that their products meet the newly established acceptable intake levels for nitrosamines and implement necessary quality control measures to keep impurities within limits.
Regulatory Intelligence Lead
Monthly
Manufacturers must ensure that nitrosamine impurities do not exceed the updated acceptable intake levels.
Manufacturers must verify that their products meet the newly established acceptable intake levels for nitrosamines and implement necessary quality control measures to keep impurities within limits.
EMA updated the acceptable intake levels for nitrosamine impurities in human medicines, establishing new limits that manufacturers must comply with to control these impurities.
What changed: EMA released an update to Appendix 1 of the nitrosamines referral, setting revised acceptable intake limits for nitrosamine impurities in human medicinal products.
Why it matters: Nitrosamine impurities are potential carcinogens; updated limits ensure patient safety and require manufacturers to reassess and control impurity levels in their products.
Practical implication: Manufacturers must verify that their products meet the newly established acceptable intake levels for nitrosamines and implement necessary quality control measures to keep impurities within limits.
Published from the Firecrawl agent regulatory extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
